Vivos Inc Updates Human Therapy Progress in India

Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel^® Precision Radionuclide Therapy^™.

Initiated in December 2024, a prominent physician in India began treating patients to demonstrate safety and measure efficacy with RadioGel^®.

Patients have continued to attend their scheduled regulatory follow-up visits in accordance with the protocol. To date, no reports of serious adverse events have been received. Several patients have now completed their one-year follow-up examinations and continue to show no reported adverse effects at these timepoints.